AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00160966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin and Mycophenolate-mofetil
Description: according to the Giessen protocol
Study NCT00160966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus and Mycophenolate-mofetil
Description: according to Giessen protocol
Study NCT00160966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus
Description: according to Giessen protocol
Study NCT01440062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verum arm receiving Vitamin D oil
Description: oil: 20000 IU/g tablet: 400 IU/g every second day
Study NCT01440062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day
Description: neutral oil and a low dose of vitamin D
Study NCT03139318 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: GRID radiotherapy
Description: Patients will be treated with GRID radiotherapy
Study NCT04243785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-A51
Description: Orally administered capsules available in strengths of 0.5 mg, 1.0 mg, 2.0 mg and 7 mg.
Study NCT04243785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered IV or SC 75 mg/m2 QD on Days 1-7 of each 28-day cycle.
Study NCT02892123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZW25 (Zanidatamab)
Description: ZW25 administered IV once weekly, once every 2 weeks, or once every 3 weeks. Part 1: in multiple increasing doses; Part 2: ZW25 given at the MTD, OBD, or an RD identified in Part 1; Part 3: ZW25 given at the MTD, OBD, or an RD combined with one of the following selected drug combination:
Study NCT02892123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Combination therapy with ZW25 - Part 3 Treatment Groups 1 and 4
Study NCT02892123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Combination therapy with ZW25 - Part 3 Treatment Groups 2 and 5
Study NCT02892123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Combination therapy with ZW25 - Part 3 Treatment Groups 3 and 6
Study NCT02892123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Combination therapy with ZW25 and Capecitabine - Part 3 Treatment Group 7
Study NCT02892123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Combination therapy with ZW25 - Part 3 Treatment Group 8 (may be opened if recommended by the Safety Monitoring Committee and/or the sponsor)
Study NCT03088215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shock-waves
Description: Application of shock-waves (radial and focused)
Study NCT01858311 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Tocotrienol Capsules
Description: Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)
Study NCT01858311 — intervention group
Intervention type: OTHER
Intervention: Placebo Vehicle
Description: Placebo capsules per day (2 in the morning and 2 in the evening)
Study NCT03488927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supporting Survivors and Self: An Intervention for Social Supports of Survivors of Partner Abuse and Sexual Aggression (SSS)
Description: The SSS intervention consists of a two-hour session followed by a 90-minute booster session a month following the initial program session. The SSS intervention is delivered in groups of approximately 20 students facilitated by peer educators. The SSS intervention provides participants with specific information on the reasons why positive social reactions are important and negative social reactions can be harmful, examples of what to say and what not to say (including ways to promote healthy coping and discourage unhealthy coping, e.g., drinking to cope), opportunities for roleplay, and an emphasis on the importance of self-care and ways in which self-care can be balanced with the needs of IPV and SA victims.
Study NCT03654443 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Critical care pain observation tool
Description: The CPOT tool is administered in a crossover manner by two study observers
Study NCT03111966 — intervention group
Intervention type: OTHER
Intervention: Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir
Description: Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir
Study NCT01367431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Xanthohumol
Description: PK study with one capsule of one of the three doses randomly assigned
Study NCT00441454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transobturator Tension-free vaginal tape (TVT-O)
Description: tension-free vaginal tape (TVT)
Study NCT00441454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Retropubic Tension-free vaginal tape (TVT)
Description: Retropubic Tension-free vaginal tape (TVT)
Study NCT03857906 — intervention group
Intervention type: DEVICE
Intervention: Intra-Aortic Ballon Pump insertion
Description: The IABP (Ultraflex IAB 7.5F, 2.5mm; Arrow International, Reading, PA) was inserted percutaneously through the right femoral artery in the previous 1 - 6 hours before the scheduled surgery. Positioning of the IABP was guided by radioscopy. The balloon size was based on the patient's height (30, 40 or 50 cc). Transesophageal echocardiography was used to confirm correct IABP placement before and after CABG
Study NCT01061983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Activa Deep Brain Stimulation
Description: In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
Study NCT03965208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: titrated continuous infusion
Study NCT03965208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: titrated continuous infusion
Study NCT00412568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photorefractive Keratectomy (PRK)
Description: vision correction with PRK
Study NCT01112891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 50 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
Study NCT03787017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC(MP-513 20mg/Metformin XR 1000mg)
Study NCT03787017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-513 20mg
Study NCT03787017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR 1000mg
Study NCT00831350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Subjects will receive study medication ranibizumab 0.5mg. Re-treatment will occur monthly through 6 injections
Study NCT04139941 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Test for HCV antibodies with an RDT
Description: Fingerstick whole blood, plasma and serum of each participant is tested with three investigational HCV RDTs and one reference HCV RDT. Plasma is also used for testing with the composite reference standard, HCV viral load and genotyping. All participants are also tested for HIV with an HIV RDT.
Study NCT01421459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OAMs
Description: Administered orally
Study NCT02458391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care complete decongestive therapy
Description: Participants will receive standard of care complete decongestive therapy consisting of meticulous skin and nail care, manual lymphatic drainage, compression bandaging, remedial exercises and self-care training.
Study NCT02563249 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight
Study NCT02563249 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: movements of the upper limb, the gripping force, muscle activity and eye-cephalic subject movement measurements
Study NCT01745094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral
Study NCT01745094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin
Description: oral
Study NCT02647515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study NCT00851006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: Creapure brand of creatine monohydrate
Study NCT00939380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention sessions
Description: Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns.
Study NCT00939380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CD-ROM
Description: Participants receive a laptop computer and a CD-ROM after the first session of behavioral intervention.
Study NCT00939380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DVD and pamphlet
Description: Participants receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD.
Study NCT00939380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respite care
Description: Participants receive 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks.
Study NCT02038452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-Medrone
Description: Steroid Injection
Study NCT02038452 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wrist Splint
Description: Simple wrist splint
Study NCT00642720 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pegvisomant
Description: if the addition of 40 mg pegvisomant weekly will improve the quality of life of acromegaly patients compared to placebo weekly
Study NCT04417088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
Study NCT02617784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir will be given as marketed oral suspension, 30 mg after HD or CAPD treatment.
Study NCT00801918 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Denileukin Diftitox
Description: Denileukin Diftitox: 18 mcg/kg/day: days 1-5 in cycles 1,2,3,4
Study NCT04417088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate BBBD
Description: BBB opening via Exablate Neuro Type 2 system with microbubble resonators.
Study NCT04318431 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Data collection and rhinopharyngeal swab
Description: Testing for SARS -Cov2 and other respiratory pathogens by PCR via nasopharyngeal swabbing and IgM/IgG rapid serology
Study NCT02865148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: CBT-based protocol tailored to advanced breast cancer patients with a focus on managing a broad array of symptoms including psychological distress, pain, and fatigue. Important features of the protocol are: 1) a unique motivational interviewing component in the first session that will focus on patients' motivation for engaging in the protocol, confidence (i.e., self-efficacy) to learn new strategies, and potential barriers to adopting recommendations for lifestyle change; and 2) protocol that targets multiple symptoms, and 3) adapted to meet the unique needs of advanced breast cancer patients.
Study NCT01868373 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Microbiota Transplantation (FMT)
Description: Active therapy
Study NCT00801918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide
Description: Denileukin Diftitox: 18 mcg/kg/day days 1-2 in cycles 5 and 6 Ifosfamide: 3000mg/m²/IV/d X 3 days + Mesna 3000 mg/m2/d X 3 days Carboplatin: 635mg/m2/d X 1 day Etoposide: 100mg/m2/d X 3 days
Study NCT00697073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients > 45 kg/99 lbs: idebenone 2250 mg/day
Study NCT02935101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: formulated for oral administration. encapsulated.
Study NCT02935101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Prednisolone)
Description: Sugar pill manufactured to mimic Prednisolon 10mg capsules
Study NCT02379923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crossing of Coronary Artery CTO
Description: Standard angiographic procedures will be followed for this study. The primary objective of this trial is to evaluate confirmation of placement of any guidewire beyond the chronic total occlusion (CTO) in the true vessel lumen in patients in which at least one Asahi series of guidewires and/or Corsair microcatheter were used.~Procedure success will be defined as angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital MACE.~Other Name: ASAHI Corsair Microcatheter, ASAHI PTCA Guide Wires
Study NCT01498835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Patients will receive Sunitinib daily for 2 weeks prior to and then concurrently with irradiation as neoadjuvant treatment. Radiotherapy will be given as intensity modulated radiation therapy with a total dose of 50.4Gy in 28 fractions to each patient (5 1/2 weeks).~Sunitinib will be given in two dose levels. The first dose level will be 25mg Sunitinib per os daily. The second dose level will be 37.5mg sunitinib per os daily. A dose modification schedule according to a 3+3 design will be applied for patient accrual.
Study NCT00697385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclokapron
Description: (2) 500mg tablets taken by mouth every 6-8 hours
Study NCT03110510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 5FU 400mg/m2 bolus and then 2400mg/m2, continuous infusion D1-2
Study NCT03110510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Irinotecan 180 mg/m2
Study NCT03110510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Leucovorin 200 mg/m2
Study NCT04698447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_MetS
Description: 20 eligible subjects with the metabolic syndrome (MetS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months and as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
Study NCT04698447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (without any active ingredients)
Description: 20 eligible subjects with the metabolic syndrome will take placebo in a spray-dried formulation (without any active ingredients) directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
Study NCT04698447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_HS
Description: 20 eligible healthy subjects (HS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months, maintained at fixed doses for the entire study.
Study NCT05562856 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: surface pre-reacted glass filler coating material
Description: the ability to improve the aesthetic appearance (masking) and caries lesion state of the WSLs
Study NCT00467610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panhematin
Study NCT03815617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zircombi
Description: Twenty-five IBS patients (Rome IV criteria) (M:F= 8:17; age 48 yrs ± 11 SD) were enrolled and randomized to treatment or placebo in a a crossover randomized double-blind two-block placebo-controlled trial. Abdominal pain and bloating, intestinal habits, severity of disease, intestinal permeability, and intestinal microbiota were performed at the different time points.
Study NCT03815617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given as comparable packets. Same duration.
Study NCT02521571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resiliance Alliance
Description: The intervention is 6 months long \& is delivered through weekly sessions held in the participating child protective offices. The sessions follow a 4-week cycle with the participants changing each week of the cycle: (1) CPS alone, by units; (2) CPS/Supervisor units; (3) Child Protective Manager and CPS/Supervisor units; and (4) CPSs \& Supervisors/Managers separately.~Participating staff are introduced to a resilience-related topic or skill, and receive a brief didactic training on that topic. Staff then engage in a group activity, which is designed to help them apply the new topic or skill to the workplace. Each module wraps up with a relaxation or exercise to help staff transition back into their work responsibilities; the facilitator can pick among the selection provided based on their sense of what would be helpful for the group. Staff are also given handouts and activities to do during the week.
Study NCT02521571 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Secondary traumatic stress training
Description: These trainings will take place in two parts (for a total of 3 hours) and include an overview of secondary traumatic stress and its impact on child welfare staff, and some strategies staff can use to protect themselves from STS - essentially a summary version of what the intervention group will receive over the 24 weeks of the intervention. The investigators consider this training to represent treatment as usual, as from our experience it is often how child welfare agencies address the issue of secondary traumatic stress among their staff.
Study NCT01539798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral saline
Description: Ingestion of 2 L of 0.9% saline solution over 1h
Study NCT01539798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous saline
Description: Infusion of 2L of 0.9% saline solution over 1h
Study NCT00986479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: Single IV infusion of 150 mg AZD6765.
Study NCT00986479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to AZD6765
Description: Single IV infusion of Placebo to AZD6765
Study NCT01304160 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy
Description: 30Gray in 5 fractions
Study NCT05562856 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: surface pre-reacted glass filler coating material
Description: the ability to improve the aesthetic appearance (masking) and caries lesion state of the WSLs
Study NCT02598973 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Aerobic walking
Study NCT00997659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chromium picolinate
Description: 1000 mg per day
Study NCT04533685 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Reminders for Influenza Vaccination: Direct scheduling link
Description: Patients receive reminder/recall messages via the patient portal to get an influenza vaccination that include a direct scheduling link, enabling the patient to directly schedule a flu vaccination only visit
Study NCT04533685 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Portal Reminders for Influenza Vaccination: No direct scheduling link
Description: Patients receive reminder/recall messages via the patient portal to get an influenza vaccination (no direct scheduling link included)
Study NCT04533685 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Commitment Prompt
Description: Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination
Study NCT04533685 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Appointment flu vaccine reminders
Description: Patients receive modified pre-appointment reminders for upcoming scheduled appointments that include language encouraging patients to ask the provider for the flu vaccine